Mesenchymal Stem Cells Market Analysis

  • Report ID: 3933
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Mesenchymal Stem Cells Market Analysis

Type (Human MSCs, Mouse MSCs, Rat MSCs)

The global mesenchymal stem cells market is segmented and analyzed for demand and supply by type into bone marrow, umbilical cord, adipose tissue, molar cell, and others. Out of the three types of irritable bowel syndrome, the umbilical cord segment is estimated to gain the largest market share in the year 2037. The growth of the segment can be attributed to the growing awareness amongst people about the high regenerative properties of umbilical cord cells, along with the increasing trend of storing the cells for the future. It is highly beneficial for treating genetic disorders, immune deficiencies, and several types of cancers. For instance, it was projected that around 450,000 people are currently living with immune deficiency diseases (PIDDs) in USA.   

Furthermore, the bone marrow segment is estimated to obtain the second-largest share of the market over the forecast period. Bone marrow mesenchymal stem cells (MSCs) have different properties than other somatic stem cells and that’s the reason they are considered to be unique types of adult stem cells. MSCs are self-renewing multipotent cells and are most suitable for bone tissue regeneration. Cell generation is used in several treatments such as Alzheimer's treatment and to cure spinal cord injuries, cancer, type 1 diabetes, osteoarthritis, Parkinson’s disease, cancer, heart disease, and others. The higher prevalence of these diseases is set to hike the demand for bone marrow mesenchymal stem cells (MSCs). As of 2019, nearly 8 million people across the globe are estimated to be living with Parkinson’s disease. Hence, all these factors are anticipated to influence segment growth positively over the forecast period.

Our in-depth analysis of the global market includes the following segments:

                 By Type

  • Human MSCs
  • Mouse MSCs
  • Rat MSCs
  • Others

            By Source

  • Bone Marrow
  • Umbilical Cord
  • Adipose Tissue
  • Molar Cells
  • Others

            By Application

  • Drug Discovery
  • Injuries
  • Cardiovascular Myocardial Infarction
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3933
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of mesenchymal stem cells is estimated at USD 4.38 billion.

The mesenchymal stem cells market size was over USD 3.93 billion in 2024 and is anticipated to cross USD 22.59 billion by 2037, witnessing more than 14.4% CAGR during the forecast period i.e., between 2025-2037. Rising demand for stem cell treatment in type 1 diabetes and the growing prevalence of genetic diseases and disorders will drive the market growth.

North America industry is set to account for largest revenue share of 43% by 2037, attributed to increasing adoption of advanced healthcare technologies in the region.

The major players in the market include Bio-Techne Corporation, Merck KGaA, Genlantis, Inc., Celprogen Corporation, PromoCell GmbH, Cyagen US Inc., Plus Therapeutics, Inc., Human Longevity, Inc., Thermo Fisher Scientific Inc., Pluristem Therapeutics Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample